Radioimmunoassayable serum somatomedin B in normal subjects and in patients with acromegaly and pituitary dwarfism: effects of human growth hormone therapy.
We report the results obtained with a radioimmunoassay for serum somatomedin B (SmB) in 29 normal subjects, in 33 pituitary dwarfs (GHD) and 6 acromegalic patients. There were no significant differences between the basal SmB levels of the GHD and the normal subjects higher value observed in the acromegalic group (p < 0.01). After acute human growth hormone administration a parallel increase of SmB serum levels and plasma growth hormone was seen (r = 0.562; p < 0.01). Of 12 GHD subjects SmB serum levels increased only in five, after chronic hGH administration.
D000172:Acromegaly / Q000097:blood* / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D002648:Child; D004393:Dwarfism, Pituitary / Q000097:blood* / Q000188:drug therapy; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D013002:Somatomedins / Q000097:blood* / Q000276:immunology
D013002:Somatomedins; C016756:somatomedin B; D013006:Growth Hormone